Pioneering neuroprotection using acute omega-3 fatty acid therapeutics Brain cell death following hypoxia-ischemia is inhibited  by the pleiotropic effects of bioactive omega-3 fatty acids  THDG3 is a novel semi-synthetic omega-3 fatty acid glyceride emulsion​ Intravenous THDG3 is a potent neuroprotectant and ​far superior to any tested omega-3 triglyceride emulsion​ The rare neonatal condition HIE is the lead indication for THDG3​ Neonatal hypoxic-ischemic encephalopathy (HIE) is the​ medical term for brain damage in newborns who have​ received too little oxygen during labor and/or delivery​
THDG3

THDG3:

A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline

THDG3

THDG3:

A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline

Indications

Neonatal hypoxic-ischemic encephalopathy (HIE)

Insufficient supply of oxygen during labor and/or delivery causes brain injury in tens of thousands of newborns every year. HIE is the most common cause of cerebral palsy in full-term infants

Indications

Ischemic stroke is the 5th most common cause of death in the US

Ischemic stroke is one of the largest and most costly unmet medical needs. Tissue plasminogen activator (t-PA) and thrombectomy can be used to restore blood flow in some patients but no neuroprotectant is approved to date

Partnering

DeckTherapeutics seeks to partner its omega-3 platform

Contact us to discuss how we together can leverage DeckTherapeutics’ world class expertise and IP in the area of acute omega-3 therapeutics

Partnering

DeckTherapeutics seeks to partner its omega-3 platform

Contact us to discuss how we together can leverage DeckTherapeutics’ world class expertise and IP in the area of acute omega-3 therapeutics